Hyponatremia is the most common electrolyte disorder found in hospitalized patients, and managing it safely is one of the most critical challenges in nephrology and internal medicine. When hyponatremia is driven by the Syndrome of Inappropriate Antidiuresis (SIAD), clinicians frequently look to specialized therapies like vasopressin receptor antagonists (VRAs like tolvaptan) or oral urea.
Until recently, direct head-to-head comparative data between these options has been remarkably scarce.
A landmark 2026 study published in Nephrology Dialysis Transplantation (NDT) by Heller, Marx, et al. provides much-needed clarity. Evaluating a large cohort of 537 hospitalized adult patients with SIAD, researchers compared the effectiveness, safety, and financial impact of oral urea versus tolvaptan.
The results offer strong validation for utilizing oral urea as a safe, highly effective, and cost-conscious first-line therapy.
The Study at a Glance
The retrospective cohort study reviewed data from 537 adult inpatients treated at a single institution between 2015 and 2023, all presenting with severe to moderate hyponatremia (baseline serum sodium <130 mmol/L).
To ensure a fair comparison, researchers utilized Inverse Probability of Treatment Weighting (IPTW) to rigorously adjust for clinical confounders between the two treatment arms:
- Urea Group: 463 patients (mean starting dose of 26 g +/-6 g daily)
- Tolvaptan Group: 74 patients (mean starting dose of 12.9 mg 6.5 +/-6 mg daily)
Key Findings: How Do They Compare?
1. Equally Effective at Correcting Sodium Levels
The primary goal of the study was to determine what percentage of patients successfully reached a safe target serum sodium level of >130 mmol/L.
The two treatments performed almost identically:
- Urea: 80% success rate
- Tolvaptan: 78% success rate
With a p-value of 0.986, the data demonstrates that oral urea is completely comparable to tolvaptan in its ultimate clinical effectiveness for correcting SIAD-driven hyponatremia.
2. Urea Significantly Reduces Dangerous Overcorrection
While raising low sodium levels is crucial, raising them too fast poses severe neurological risks, such as Central Pontine Myelinolysis (CPM). The study closely monitored overcorrection rates (defined as an increase of >10 mmol/L within a 24-hour period).
- Tolvaptan did raise sodium faster at the 48-hour mark (8.3mmol/L vs 5.6 mmol/L)
- However, this rapid rise came with a steep safety trade-off: 10.8% of tolvaptan patients experienced dangerous overcorrection.
- In stark contrast, only 3.2% of oral urea patients overcorrected.
This statistically significant difference (p = 0.011) highlights oral urea as a more predictable, stable, and safer option for managing sodium upward trends.
3. Shorter Treatment Durations and Monumental Cost Savings
Beyond safety and efficacy, the study looked closely at healthcare resource utilization. Tolvaptan therapy required a significantly longer median treatment duration than urea (7 days vs. 5 days, p = 0.001).
The most staggering divergence, however, was the financial impact:
- Tolvaptan Median Cost: €468
- Oral Urea Median Cost: €12
At a mere fraction of the price (p < 0.001), oral urea achieved the exact same clinical destination while heavily reducing the financial burden on the healthcare system and the patient.
The Takeaway for Clinicians and Patients
The authors concluded that oral urea exhibits a highly comparable effectiveness to tolvaptan, but boasts a far superior safety profile regarding overcorrection and vastly superior cost-efficiency.
For providers managing SIAD, these findings strongly support moving oral urea to the front of the line. It delivers the same reliable clinical results as expensive brand-name pharmaceuticals, cuts down on hospital resource utilization, and fundamentally protects patients from the risky “overshoot” of rapid sodium correction.
At UreaAide, we are proud to continue supporting the medical community with highly accessible, reliable oral urea options that align perfectly with modern, evidence-based nephrology practice.
Reference: Heller, M., Marx, K. et al. Urea vs. tolvaptan for hospitalized patients with SIAD. Nephrology Dialysis Transplantation (2026).